JavaScript is NOT enabled !

Please enable JavaScript.

Article

FT
PubMed

This record comes from PubMed

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Wenzel, Mike
Author Wenzel, Mike ORCID Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada. Mike.Wenzel@kgu.de
Nocera, Luigi
Author Nocera, Luigi ORCID Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
Collà Ruvolo, Claudia
Author Collà Ruvolo, Claudia ORCID Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
Würnschimmel, Christoph
Author Würnschimmel, Christoph ORCID Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Tian, Zhe
Author Tian, Zhe Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada
Shariat, Shahrokh F
Author Shariat, Shahrokh F ORCID Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York, NY, USA Department of Urology, University of Texas Southwestern, Dallas, TX, USA Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czechia Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
Saad, Fred
Author Saad, Fred Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada
Tilki, Derya
Author Tilki, Derya ORCID Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Graefen, Markus
Author Graefen, Markus Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Kluth, Luis A
Author Kluth, Luis A Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
Briganti, Alberto
Author Briganti, Alberto Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
Mandel, Philipp
Author Mandel, Philipp Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
Montorsi, Francesco
Author Montorsi, Francesco Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
Chun, Felix K H
Author Chun, Felix K H Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
Karakiewicz, Pierre I
Author Karakiewicz, Pierre I Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada

Prostate cancer and prostatic diseases. 2023 Dec ; 26 (4) : 807-808.

Prostate Cancer Prostatic Dis
ISSN 1476-5608 | 1365-7852
Source

Status PubMed-not-MEDLINE Language English Country Great Britain, England Media print

Document type Published Erratum

Persistent link https://www.medvik.cz/link/pmid36899091

Online Full text

PubMed 36899091
PubMed Central PMC10638077
DOI 10.1038/s41391-023-00656-4
PII: 10.1038/s41391-023-00656-4
Knihovny.cz E-resources

Publication type
Published Erratum MeSH

Department of Neurosciences Reproductive Sciences and Odontostomatology University of Naples Federico 2 Naples Italy

Department of Urology 2nd Faculty of Medicine Charles University Prag Czechia

Department of Urology and Division of Experimental Oncology URI Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Goethe University Hospital Frankfurt Frankfurt am Main Germany

Department of Urology University Hospital Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Cancer Prognostics and Health Outcomes Unit University of Montréal Health Center Montréal QC Canada

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany

Erratum For

Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. PubMed

References provided by Crossref.org

Borrow
RIS

Find record

In BMC

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Find record

Citation metrics

Archiving options